Quarterly report (Form 10-Q)
Edwards Lifesciences 10-Q for Quarter ended Jun 30, 2026
Filing excerpt
Net cash used in investing activities of $286.0 million for the six months ended June 30, 2026, consisted primarily of capital expenditures of $131.8 million, issuance of notes receivable of $53.2 million, and net payments of $33.7 million related to business combinations, partially offset by net purchases of investments of $63.0 million.